Trial results

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

NCT06299098 on ClinicalTrials.gov · last registry update 2026-09-01

An unusually large phase 2: 1,005 participants, more than double the 114 typical for the stage. The sponsor logged completion for 16 June 2026. Primary outcome, as filed: Incidence of treatment-emergent adverse events (TEAEs). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Regeneron Pharmaceuticals

Sponsor type

Industry

Enrollment

1,005

Started

2024-03-13

Primary completion

2026-06-16 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Incidence of treatment-emergent adverse events (TEAEs)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.